Griffin Stephen D. 4

What Happened

• Stephen D. Griffin, President & CEO and a director of Anika Therapeutics (ANIK), was granted derivative equity awards on 2026-02-01. The filing shows two awards: 310,207 units and 130,402 units, each reported with a $0.00 acquisition price (derivative awards, not open-market purchases). The combined total of the awards is 440,609 units.
• These are compensation awards (not sales or purchases). One award is a Stock Appreciation Right (SAR) structure and the other is a Restricted Stock Unit (RSU) structure (see Key Details for vesting/settlement terms).

Key Details

• Transaction date: 2026-02-01; Form 4 filed: 2026-02-03 (timely — within the usual two-business-day window).
• Reported price: $0.00 for both awards (code A — grant/award).
• Total units granted: 310,207 + 130,402 = 440,609 derivative units.
• Shares owned after transaction: not reported in the supplied filing excerpt.
• Footnotes of note:
  • F1: Includes 800 shares acquired Nov 14, 2025 under the company ESPP.
  • F2: The SAR may be settled in cash, shares, or a combination (per the 2017 Omnibus Incentive Plan).
  • F3: The award that vests over time does so in three equal annual installments, with first vesting on Feb 1, 2027, subject to continued service.
  • F4: Each RSU is the contingent right to receive one share (or cash equivalent) on the vesting date.
• Transaction code: A = Award/Grant (compensation). Not a purchase (P) or sale (S).

Context

• SARs: give the holder the right to receive the appreciation in the stock price, payable in cash, stock, or both — value depends on future stock performance.
• RSUs: are rights to receive shares (or cash equivalent) on vesting dates; they do not represent current share ownership until settled/vested.
• These awards reflect compensation to the CEO and are routine for executives; they are not the same signal as an insider buying shares on the open market.